44
Participants
Start Date
May 31, 2015
Primary Completion Date
September 29, 2017
Study Completion Date
September 29, 2017
I10E
"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
Hospital Quiron Madrid, Madrid
CHU de Bordeaux - Hôpital Pellegrin, Bordeaux
Hôpital général du CHU de Dijon, Dijon
CHU de Nice - Hôpital l'Archet, Nice
CHU Paris - Hôpital Pitié salpétrière, Paris
Hôpital Pontchaillou, Rennes
CHU de saint Etienne - Hôpital nord, Saint-Etienne
Hôpital de Hautepierre, Strasbourg
IRRCS Azienda Ospedaliera Universitaria, Genova
IRCCS - Istituto Clinico Humanitas, Milan
IRRCS Istituto Nazionale Neurologico Besta, Milan
Ospedale San Raffaele IRCCS, Milan
Azienda Ospedaliere Universitaria di Padova, Padua
Università Cattolica del Sacro Cuore, Roma
Azienda Ospedaliere Universitaria san Giovanni, Torino
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital General Universitario Gregorio, Madrid
Hospital clinico Universitario de Santiago, Santiago de Compostela
Hospital Universitario Virgen del Rocio, Seville
Hospital Universitario i Politècnico La Fe, Valencia
Hôpital Razi, La Manouba, Manouba
Hôpital Fattouma Bourguiba, Monastir
Hôpital habib Bourguiba, Sfax
Hôpital Sahloul, Sousse
Hôpital militaire de Tunis, Tunis
Ankara University medical School Neurology, Ankara
Hacettepe University Medical School Neurology, Ankara
Uludag University Medical School Neurology, Bursa
Istanbul UniversityCerrahpasa Medical School Neurology, Istanbul
Marmara Universitesi Egitim Ve Arastirma Hastanesi, Istanbul
Southampton General Hospital, Southampton
University Hospital of North Straffordshire, Stratford-upon-Avon
St Georges, London
Laboratoire français de Fractionnement et de Biotechnologies
INDUSTRY